When was ADmit Therapeutics founded?

ADmit Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is ADmit Therapeutics located?

ADmit Therapeutics is headquartered in Barcelona, Spain.

How many employees does ADmit Therapeutics have?

As of Jul 01, 2024, the latest employee count at ADmit Therapeutics is 7.

Is ADmit Therapeutics a funded company?

ADmit Therapeutics is a funded company, having raised a total of $12.9M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 09, 2018.

When was the latest funding round of ADmit Therapeutics?

ADmit Therapeutics' latest funding was a $***** Series A round on Oct 05, 2023, with participation from 6 investors.

Where does ADmit Therapeutics rank among its competitors?

ADmit Therapeutics ranks 3rd amongst 66 active competitors, of which 23 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Arima Genomics, which secured $22M in Jun, 2025.

Who are the top competitors of ADmit Therapeutics?

ADmit Therapeutics' top competitors include Oxford Biodynamics, Arima Genomics and C₂N Diagnostics. Among them, Arima Genomics secured the most recent funding round in June, 2025.

ADmit Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of diagnostic services for early detection of Alzheimer's disease. The company is developing diagnostic tests by using next-generation sequencing analysis for the detection of biomarkers β-amyloid nor tau. The test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA.

Website: admit-therapeutics.com/en/
Social
Email ID: *****@admit-therapeutics.com
Phone Number: +34 **********

Key Metrics

Founded Year

2017

Location

Barcelona, Spain

Stage

Series A

Total Funding

$12.9M in 5 rounds

Latest Funding Round

Series A, Oct 05, 2023, $*****

Investors

Ship2B & 14 more

Ranked

3^rd among 66 active competitors

Employee Count

7 as on Jul 01, 2024

Similar Companies

Oxford Biodynamics & 94 more

View ADmit Therapeutics' full profile

ADmit Therapeutics has raised a total funding of $12.9M over 5 rounds. Its first funding round was on Aug 09, 2018. Its latest funding round was a Series A round on Oct 05, 2023 for $*****. 6 investors participated in its latest round. ADmit Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of ADmit Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 05, 2023	9831552	Series A	9894330	2122185	1476880	5208512
Jan 01, 2021	2248446	Grant (prize money)	8264562	8034830	5172951	Europa
Aug 31, 2020	8704779	Series A	8488124	3347369	Ship2B	Capital Cell

Access funding benchmarks and valuations. Sign up today!

View details of ADmit Therapeutics's funding rounds and investors

The founders of ADmit Therapeutics is Jordi Gascon.

Here are the details of ADmit Therapeutics' key team members:

Jordi Gascon: Co-Founder of ADmit Therapeutics.
Contact Info: 1 email address

View details of ADmit Therapeutics's Founder profiles and Board Members

ADmit Therapeutics' employee count trend

ADmit Therapeutics has 7 employees as of Jul 24. Here is ADmit Therapeutics's employee count trend over the years:

Employee count trend for ADmit Therapeutics

Uncover ADmit Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ADmit Therapeutics include Oxford Biodynamics, Arima Genomics and C₂N Diagnostics. Here is the list of Top 10 competitors of ADmit Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	57/100
2nd	Arima Genomics 2015, San Diego (United States), Series C	Developer of technologies for genome sequence and structure	$29M	Illumina Ventures, Ladder Ventures & 10 others	57/100
3rd	ADmit Therapeutics 2017, Barcelona (Spain), Series A	Provider of diagnostic services for early detection of Alzheimer's disease	$12.9M	Additio Ventures, GENESIS Biomed & 13 others	57/100
4th	C₂N Diagnostics 2007, St. Louis (United States), Series B	Developer of diagnostics and therapies for Alzheimer's disease	$35M	Eisai, Samsung BioLogics & 6 others	56/100
5th	Sherlock 2019, Watertown (United States), Acquired	Provider of a diagnostic platform for DNA and RNA detection	$111M	Baidu Ventures, Novalis LifeSciences & 11 others	55/100
6th	Amydis Diagnostics 2013, San Diego (United States), Series A	Developer of diagnostics test for detection of Alzheimer's disease	$8.69M	NIA, JLABS & 3 others	52/100
7th	Tagomics 2020, Birmingham (United Kingdom), Series A	Developer of genomic-based cancer diagnostic platform	$8.45M	Calculus Capital, Illumina Ventures & 7 others	51/100
8th	Age Labs 2017, Oslo (Norway), Seed	Developer of molecular diagnostic solutions for the detection of age-related diseases	$876K	Skyfall Ventures, Aleap & 2 others	50/100
9th	Todos Medical 2009, Rehovot (Israel), Public	Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders	-	Lincoln Park Capital, Yozma & 2 others	48/100
10th	DiamiR 2009, Monmouth Junction (United States), Funding Raised	Developer of minimally invasive diagnostic tests	-	NIA, HHS	47/100